# Oral Sessions

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/oral-sessions/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Patients with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA) struggle to maintain wakefulness. Solriamfetol (Sunosi®) is a dopamine/norepinephrine reuptake inhibitor with agonistic properties at TAAR1 and serotonin 1A receptors; it is approved to treat EDS associated with narcolepsy (75–150 mg/day) or OSA (37.5–150 mg/day). This post-hoc analysis characterized the effects of solriamfetol on the propensity of participants with EDS associated with narcolepsy or OSA to maintain wakefulness. |
| Citations | 0 |
| DOI | 10.1111/jsr.14290 |
| Fields | Neuroscience,Psychology |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jsr.14290 |
| OpenAlex ID | https://openalex.org/W4402724872 |
| Type | article |
| Year | 2024 |

## Paper journal

- [Journal of Sleep Research](https://scholariq.org/journals/journal-of-sleep-research/)

## Paper primary topic

- [Sleep and Wakefulness Research](https://scholariq.org/topics/sleep-and-wakefulness-research/)

## Paper topics

- [Sleep and Wakefulness Research](https://scholariq.org/topics/sleep-and-wakefulness-research/)
- [Sleep and related disorders](https://scholariq.org/topics/sleep-and-related-disorders/)
- [Sleep and Work-Related Fatigue](https://scholariq.org/topics/sleep-and-work-related-fatigue/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.